AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00271505
Drug: Bevacizumab (Avastin)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15 mg/kg intravenously (IV) every 3 weeks
Trial: NCT00271505
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC 6 IV every 3 weeks
Trial: NCT00271505
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 IV every 3 weeks
Trial: NCT01537614
Drug: COLIMYCINE inhalation
RxNorm normalized name: Colimycin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 MILLION UI
Trial: NCT01537614
Drug: COLIMYCINE injectable
RxNorm normalized name: Colimycin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 MILLIONS UI
Trial: NCT03309176
Drug: Medroxyprogesterone Acetate 10 MG
RxNorm normalized name: medroxyprogesterone acetate 10 MG
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
Trial: NCT00539188
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
Trial: NCT02356900
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used in Hyperoxic hyperbaric interval exercise training intervention
Trial: NCT00047645
Drug: Interferon-gamma 1b
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg, SQ, 3x per week
Trial: NCT00508664
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
Trial: NCT00508664
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 i.v. day 1 3 times
Trial: NCT00508664
Drug: Cisplatin (TP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2 i.v. day 1 3 times
Trial: NCT00508664
Drug: 5-Fluorouracil (TPF) (only until Feb 2009)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
Trial: NCT04636983
Drug: BV100
RxNorm normalized name: Bempedoic Acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rifabutin IV
Trial: NCT00272025
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg to 20mg tablet daily for 6 weeks
Trial: NCT00749047
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-45 mg/day
Trial: NCT00612807
Drug: As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)
Trial: NCT02766140
Drug: SHR1020 plus Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
Trial: NCT02766140
Drug: Placebo plus Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m\^2 IV Day1/3weeks
Trial: NCT02027090
Drug: Routine dose icotinib
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icotinib is administered 125 mg three times daily.
Trial: NCT02027090
Drug: Higher dose icotinib
RxNorm normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
Trial: NCT01559740
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
Trial: NCT00947960
Drug: Triheptanoin
RxNorm normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
Trial: NCT00645437
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00932828
Drug: Peanut oral immunotherapy
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defatted peanut in flour form to be used as treatment for peanut allergy
Trial: NCT02674568
Drug: Rovalpituzumab tesirine
RxNorm normalized name: Rovalpituzumab tesirine
DrugBank: Rovalpituzumab tesirine (DB13017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
Trial: NCT00541814
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target drug level 50-100 ng/ml or cyclosporine withdrawal
Trial: NCT00171522
Drug: Tegaserod and Polyethylene Glycol 3350
DrugBank: Tegaserod (DB01079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01008423
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide will be administered as per the dose and schedule specified in the respective arm.
Trial: NCT00439738
Drug: HCTZ + Amlodipine
RxNorm normalized name: amlodipine / hydrochlorothiazide / valsartan
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules~* 5 mg amlodipine capsules~* 10 mg amlodipine capsules
Trial: NCT00439738
Drug: Valsartan/HCTZ
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * 160 mg film-coated valsartan tablets~* 320 mg film-coated valsartan tablets~* 12.5 mg HCTZ capsules~* 25 mg HCTZ capsules
Trial: NCT02560025
Drug: Alisertib
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02560025
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02560025
Drug: Idarubicin
RxNorm normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02560025
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Can be used in place of idarubicin
Trial: NCT00147836
Drug: Human Insulin (Novolin-R, Novo Nordisk)
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00147836
Drug: Novolin-R
RxNorm normalized name: INSULIN REG NOVOLIN-R 100UNIT/ML PEN 3ML
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00147836
Drug: Gliclazide (Diamicron, Servier)
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04231370
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab, 200mg, iv day1
Trial: NCT04231370
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25mg/d oral d1-14
Trial: NCT01316068
Drug: intravenous use of sulodexide followed by oral use
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
DrugBank: Sulodexide (DB06271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.
Trial: NCT01316068
Drug: use of sulodexide orally only
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Sulodexide (DB06271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive 1000 LSU per day orally for 52 weeks
Trial: NCT02365233
Drug: DPP4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Trial: NCT02365233
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Trial: NCT02365233
Drug: Lantus insulin
RxNorm normalized name: insulin glargine Injectable Solution [Lantus]
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
Trial: NCT01286961
Drug: bowel preparation using split dose of polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
Trial: NCT00605956
Drug: NatrOVA Creme Rinse Vehicle Only
RxNorm normalized name: Natroba
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NatrOVA Creme Rinse Vehicle - no spinosad
Trial: NCT00470509
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 subcutaneous injections on day 0 and 7
Trial: NCT00934843
Drug: methylprednisolone (IVMP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
Trial: NCT00934843
Drug: methylprednisolone (two doses IVMP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
Trial: NCT01030666
Drug: 0.12% chlorhexidine gluconate solution
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
Trial: NCT01030666
Drug: 1% chlorhexidine gluconate gel (if necessary)
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
Trial: NCT03675854
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 weeks
Trial: NCT03841747
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg Pembrolizumab IV Q3W.
Trial: NCT03841747
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle.
Trial: NCT00626574
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
Trial: NCT00626574
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
Trial: NCT00869726
Drug: dirucotide
RxNorm normalized name: Dirucotide
DrugBank: Dirucotide (DB04921)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg, intravenous, dosed once every six months for 18 months
Trial: NCT01683331
Drug: Insulin treatment for hyperglycemia
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00558831
Drug: Benzoyl Peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl Peroxide 2.5%
Trial: NCT00645450
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
Trial: NCT02172417
Drug: Cimetidine + Tiotropium
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02172417
Drug: Ranitidine + Tiotropium
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02172417
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00040300
Drug: Racivir
RxNorm normalized name: Racivir
DrugBank: Racivir (DB12753)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02220088
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accept sorafenib.
Trial: NCT03658876
Drug: Epoetin Beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
Trial: NCT02997241
Drug: chemotherapy for colorectal carcinoma
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy for colorectal carcinoma
Trial: NCT00644891
Drug: cefdinir (Omnicef)
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
Trial: NCT00644891
Drug: amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
Trial: NCT03007004
Drug: Botulinum toxin type B (2500 units / vial)
RxNorm normalized name: botulinum toxin type B
DrugBank: Botulinum toxin type B (DB00042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTX-B (E2014, Eisai, NerBloc®) was injected subcutaneously from the palmar side into seven locations around interphalangeal metacarpophalangeal joints, targeting the neurovascular bundles just proximal to the A1 pulley (the radial and ulnar sides of the first finger, the radial side of second finger, the ulnar side of the fifth finger and between the second to fifth fingers). Three locations between the second and third fingers, the third and fourth fingers, and the fourth and fifth fingers were injected with 400 U (0.2 ml) of BTX-B. In addition, the radial and ulnar sides of the first finger, the radial side of the second finger, and the ulnar side of the fifth finger were injected with half a dose of BTX-B (200 units; 0.1 ml). A total of 2000 U (1.0 ml) of BTX-B was injected into one hand. Injections were performed using a 30-gauge needle.
Trial: NCT00043342
Drug: interferon gamma-1b
RxNorm normalized name: Interferon Gamma-1B
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 or 200 mcg, SQ, 3x per week
Trial: NCT02711917
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol consumption
Trial: NCT02711917
Drug: Etomidate
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etomidate consumption
Trial: NCT02711917
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consumption of Rocuronium
Trial: NCT04591678
Drug: nusinersen
RxNorm normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
Trial: NCT00421369
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03180632
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receives one or two tablet of 0,5mg Lorazepam according to body weight
Trial: NCT00421369
Drug: triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00421369
Drug: reboxetine
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00648739
Drug: Samalizumab
RxNorm normalized name: Samalizumab
DrugBank: Samalizumab (DB12636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samalizumab is a humanized anti-CD200 monoclonal antibody.
Trial: NCT02889367
Drug: Odalasvir 100 mg
RxNorm normalized name: Odalasvir
DrugBank: Odalasvir (DB13041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive odalasvir 2\*50 mg tablet, orally once on Day 1.
Trial: NCT02889367
Drug: Odalasvir 500 mg
RxNorm normalized name: Odalasvir
DrugBank: Odalasvir (DB13041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive odalasvir 10\*50 mg tablet, orally once on Day 1.
Trial: NCT02889367
Drug: Odalasvir (Up to maximum 1000 mg)
RxNorm normalized name: Q-Up
DrugBank: Odalasvir (DB13041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive odalasvir to be decided up to maximum of 20\*50 mg tablet, orally once on Day 1.
Trial: NCT00337155
Drug: Radium-223 dichloride (BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
Trial: NCT03731117
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period
Trial: NCT04285736
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ivabradine (5mg twice daily)
Trial: NCT04285736
Drug: Conventional Treatment
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00470249
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At a dose equivalent to an area under the concentration-time curve of 4.5 mg/ml.min on day 1 of every 2-week cycle
Trial: NCT00470249
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500 mg/m2 on day 2 of every 2-week cycle
Trial: NCT04679415
Drug: Placebo (Normal saline solution)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: 0.9% NaCl Solution Frequency: Dose at Day 1, 3, 7
Trial: NCT00988039
Drug: Aluvia + 2NRTIs
RxNorm normalized name: Aluvea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy.